GoodRx (NASDAQ:GDRX) Stock Price Down 7.5% – What’s Next?

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s stock price fell 7.5% on Friday . The company traded as low as $4.18 and last traded at $4.22. 1,135,327 shares traded hands during trading, a decline of 20% from the average session volume of 1,422,404 shares. The stock had previously closed at $4.56.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. UBS Group reduced their target price on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research note on Friday, August 9th. Barclays cut their price target on GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Monday. Citigroup reduced their price target on GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target on shares of GoodRx in a research report on Friday, August 16th. Finally, Raymond James raised shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target on the stock in a report on Friday, August 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.86.

GoodRx Trading Down 9.2 %

The stock’s 50 day simple moving average is $6.62 and its 200 day simple moving average is $7.44. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The firm has a market cap of $1.57 billion, a PE ratio of -139.67, a PEG ratio of 3.22 and a beta of 1.39.

Insider Activity at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 4.17% of the stock is owned by insiders.

Institutional Investors Weigh In On GoodRx

A number of institutional investors have recently made changes to their positions in the business. Beacon Capital Management LLC bought a new position in shares of GoodRx in the first quarter worth approximately $28,000. nVerses Capital LLC bought a new position in shares of GoodRx during the third quarter valued at about $33,000. Plato Investment Management Ltd purchased a new stake in shares of GoodRx during the second quarter worth about $43,000. Dark Forest Capital Management LP bought a new stake in shares of GoodRx in the second quarter worth about $86,000. Finally, EntryPoint Capital LLC raised its position in GoodRx by 165.2% during the 1st quarter. EntryPoint Capital LLC now owns 18,538 shares of the company’s stock valued at $132,000 after purchasing an additional 11,548 shares during the last quarter. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.